Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + regorafenib + tirelizumab for advanced hepatocellular carcinoma
ChiCTR2200063134Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Objective response rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
regorafenibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200063134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063134.